Monitoring of disease response to treatment
Implantable devices monitor physiological changes to assess treatment efficacy, addressing the challenge of determining disease response to therapy.
Patent Information
- Application Number
- PCT/US2024/042922
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-08-19
- Filing Date
- 2024-08-19
- Publication Date
- 2025-02-27
AI Technical Summary
There is a need to determine the efficacy of therapeutic treatments for diseases by monitoring changes in physiological characteristics over time.
Implantable devices that measure physiological characteristics such as temperature, pH, oxygen levels, and glucose levels are used to monitor changes before and after treatment, allowing for the assessment of treatment efficacy.
This approach enables the effective monitoring of disease response to treatment, allowing for timely adjustments to treatment protocols based on changes in physiological characteristics.
Smart Images

Figure US2024042922_27022025_PF_FP_ABST
Abstract
Description
[0001] MONITORING OF DISEASE RESPONSE TO TREATMENT
[0002] TECHNICAL FIELD
[0003] This document pertains generally, but not by way of limitation, to monitoring of patient response to medical treatment.
[0004] BACKGROUND
[0005] Temperature changes in the body have been recognized as an indicator of many diseases for centuries. For cancerous tumors, localized temperature variations, both within the tumor and the body, are common due to changes in blood perfusion and metabolic heat generation.
[0006] SUMMARY
[0007] The present inventors have recognized, among other things, that a problem to be solved can include determining efficacy of a therapeutic treatment of a disease. The present subject matter can help provide a solution to this problem, such as by monitoring response of one or more physiological characteristics to the therapeutic treatment of the disease. For example, one or more devices may be implanted in a human (or animal) subject. The devices may facilitate determination of medical diagnostic information over a course of medical treatment of the subject. In an example, the one or more devices measure one or more physiological characteristics of the subject; for instance, temperature, pH, oxygen (e.g., one or more of partial pressure of oxygen (“pO2”), superoxide anions, reactive oxygen species, or the like) or glucose level.
[0008] The one or more physiological characteristics may change in response to treatment of a disease. A change in the physiological characteristics may indicate a treatment is effective against the disease. For example, a first device configured for measuring one or more physiological characteristics may be implanted at a target location within a subject, for instance implanted within abnormal or cancerous tissue of the subject. A medical treatment may be applied to the subject, for example to treat the cancerous tissue of the subject. The physiological characteristics of the subject at the target location may be measured before treatment. The physiological characteristics of the subject at the target location may be measured after treatment. The physiological characteristics of the subject before treatment may be compared to the physiological characteristics of the subject after treatment to determine a change in the physiological characteristics in response to the treatment. In another example, the physiological characteristics are monitored after treatment, for example at a first time after treatment and a second time after treatment. The physiological characteristics at the first time may be compared with the physiological characteristics at the second time to determine a change in the physiological characteristics in response to the treatment. Accordingly, the first device facilitates monitoring of physiological characteristics in response to treatment of a disease. Thus, efficacy of the treatment against the disease may be ascertained based on one or more changes in one or more physiological characteristics.
[0009] This overview is intended to provide an overview of subject matter of the present patent application. It is not intended to provide an exclusive or exhaustive explanation of the invention. The detailed description is included to provide further information about the present patent application.
[0010] BRIEF DESCRIPTION OF THE DRAWINGS
[0011] In the drawings, which are not necessarily drawn to scale, like numerals may describe similar components in different views. Like numerals having different letter suffixes may represent different instances of similar components. The drawings illustrate generally, by way of example, but not by way of limitation, various embodiments discussed in the present document.
[0012] Figure 1 shows a schematic diagram of an example of a device for measuring one or more physiological characteristics of a subject.
[0013] Figure 2 shows a schematic diagram of an example of a first device and a second device implanted in the subject.
[0014] Figure 3 shows a schematic diagram of a physiological characteristic monitoring system.
[0015] Figure 4 shows a flowchart of a method of using one or more human-implanted or animal-implanted devices for determining medical diagnostic information over a course of treatment of a human or animal subject.
[0016] Figure 5 shows a flowchart of an example of a computer- implemented method for monitoring a subject of a medical treatment.
[0017] Figure 6 shows a schematic diagram of another example of the system of Figure 3.
[0018] Figure 7 shows a block diagram of an example machine upon which any one or more of the techniques discussed herein may perform.
[0019] DETAILED DESCRIPTION
[0020] Figure 1 shows a schematic diagram of an example of a device 100 for measuring one or more physiological characteristics of a subject. The device 100 may include one or more sensors 102. The device 100 may include a device body 104. The device body 104 may include the sensors 102. For example, the device body 104 may partially or fully encapsulate (e.g., contain, encompass, surround, enclose, envelop, or the like) the sensors 102. The device 100 may be implanted into a human or animal subject, for instance implanted into tissue of the subject. The device 100 may be entirely implanted into the human or animal subject. For instance, the device 100 may be entirely contained within the subject. In another example, implantation of the device 100 does not include components outside skin of the subject 200 (e.g., the device may be implanted underneath the skin of the subject 200 so that no portion of the device 100 is outside the skin of the subject 200.
[0021] In yet another example, implantation of the device 100 may include the device 100 entirely contained within tissue of an organ of the subject 200. For instance, the device 100 may be sized and shaped for insertion into lung tissue or bladder tissue. In this example, the device 100 may be entirely contained within the lung tissue or the bladder tissue. In another example, the device 100 does not include a pacemaker, defibrillator, or the like. For instance, the device 100 may be substantially smaller than a pacemaker or a defibrillator, for example to facilitate insertion of the device 100 into tissue in correspondence with the tissue entirely containing the device 100. In a further example, the device 100 may be an oncology monitoring device, for instance a post-operative (or post-implantation) oncology monitoring device. In a still further example, the device 100 may be an implantable fiducial marker. For instance, the device 100 may be imageable in one or more imaging modalities, for example X-ray, CT scan, MRI, or the like. In yet another example, the device 100 may include a contrast agent, for instance to enhance perception of the
[0022] The sensors 102 may measure one or more physiological characteristics of a human or animal subject. In an example, the sensors 102 may include a temperature sensor 106. The temperature sensor 106 may measure temperature of a subject (or temperature of tissue of the subject). In another example, the sensors 102 may include a pH sensor 108. The pH sensor 108 may measure pH of the subject (or pH of tissue of the subject). In yet another example, the sensors 102 may include an oxygen sensor 110. In an example, the oxygen sensor 110 may detect one or more of partial pressure of oxygen (“pO2”), superoxide anions, reactive oxygen species, or the like). The oxygen sensor 110 may measure partial pressure of oxygen of a subject (or partial pressure of oxygen of tissue of the subject). In still yet another example, the sensors 102 may include a glucose level sensor 112. The glucose level sensor 112 may measure glucose level of the subject (or glucose level of tissue of the subject). Accordingly, the sensors 102 may respectively measure one or more physiological characteristics of a subject (or physiological characteristics of tissue of the subject); for example temperature, pH, oxygen, or glucose level.
[0023] The device 100 may include a device sensor interface 114. The device sensor interface 114 may communicate with the sensors 102. For example, the device sensor interface 114 may receive measured physiological characteristics from the sensors 102. In another example, the device sensor interface 114 may communicate the measured physiological characteristics (provided by the sensors 102). For instance, the device sensor interface 114 may communicate the measured physiological characteristics to allow for storage (or processing) of the measured physiological characteristics. Thus, the device 100 may communicate the measured physiological characteristics to components of a system, for example a physiological characteristic monitoring system (shown in Figure 3). Figure 2 shows a schematic diagram of an example of a first device 100 A and a second device 100B implanted in a subject 200. The subject 200 may include a human or an animal. The first device 100 A may include the device 100 (shown in Figure 1). The second device 100B may include the device 100. Accordingly, the first device 100 A and the second device 100B may measure physiological characteristics of the subject 200.
[0024] The first device 100 A may be implanted at a first location in the subject, for instance implanted at a target location 202 in the subject 200. The first device 100A may measure physiological characteristics of the subject 200 proximate to the first device 100A (or physiological characteristics of tissue of the subject 200 proximate to the first device 100 A). For example, the target location 202 may include cancerous tissue, and the first device 100 A may measure physiological characteristics of the cancerous tissue. In another example, the target location 202 may include abnormal tissue (e.g., diseased tissue, cancerous tissue, pre- cancerous tissue, or the like), and the first device 100 A may measure physiological characteristics of the abnormal tissue.
[0025] The second device 100B may be implanted at a second location in the subject 200, for instance implanted at a control location 204 in the subject 200. The second device 100B may measure physiological characteristics of the subject 200 proximate to the second device 100B (or physiological characteristics of tissue of the subject 200 proximate to the second device 100B). For instance, the control location 204 may include non-cancerous tissue, and the second device 100B may measure physiological characteristics of the non- cancerous tissue. In another example, the target location 202 may include healthy (e.g., non-diseased, or the like) tissue, and the second device 100B may measure physiological characteristics of the healthy tissue.
[0026] Figure 3 shows a schematic diagram of a physiological characteristic monitoring system 300 (“system 300”). The system 300 may include one or more of the first device 100 A or the second device 100B. The first device 100 A (or the second device 100B) may communicate with other components of the system 300, for example to communicate measured physiological characteristics to the other components of the system 300. In another example, the first device 100A (or the second device 100B) may communicate a unique identifier (e.g., a unique serial number, or the like) to other components of the system 300. The unique identifier may be associated with a specific device, for instance the first device 100 A or the second device 100B. For example, a first unique identifier may be associated with the first device 100 A, and a second unique identifier may be associated with the second device 100B. The first and second unique identifiers may facilitate differentiation between a first set of measured physiological characteristics (measured by the first device 100A) and a second set of measured physiological characteristics (measured by the second device 100B).
[0027] The first device 100 A may communicate with a device reader 302 of the system 300. The first device 100A may communicate measured physiological characteristics to the device reader 302. For instance, the device reader 302 may interrogate the first device 100 A, and the first device 100 A may communicate the measured physiological characteristics in response to interrogation by the device reader 302.
[0028] For example, the first device 100A may be passive (e.g., the first device 100 A may lack a battery, or the like), and the device reader 302 may supply energy to the first device 100 A to facilitate communication of the measured physiological characteristics to the device reader 302. Passivity of the first device 100 A may help minimize the size of the first device 100 A and accordingly allow the first device 100 A to be implanted in a wide range of locations in the subject 200 (shown in Figure 2). The device reader 302 may generate an electromagnetic signal, and the first device 100 A may receive the electromagnetic signal. In an example, the device sensor interface 114 (shown in Figure 1) may receive the electromagnetic signal generated by the device reader 302, and the reception of the electromagnetic signal by the device sensor interface 114 may correspondingly provide power to the sensors 102 (shown in Figure 1). The device sensor interface 114 may receive measured physiological characteristics from the sensors 102, and communicate the measured physiological characteristics to the device reader 302.
[0029] In another example, the first device 100A may be active (e.g., the first device 100 A may include a battery, or the like), and the first device 100 A may communicate with the device reader 302 without the device reader 302 supplying energy to the first device 100 A. In an example where the first device 100A is active, the active first device 100A may facilitate different forms of communication between the first device 100 A and other components of the system 300, for instance the device reader 302. In an example, the device sensor interface 114 may receive measured physiological characteristics from the sensors 102, and the interface 114 may generate an electromagnetic signal to communicate the measured physiological characteristics to the device reader 302.
[0030] The device reader 302 may communicate with a database and information processing system 304. For example, the device reader 302 may communicate measured physiological characteristics (received from one or more of the first device 100 A or the second device 100B) to the database and information processing system 304. In an example, the database and information processing system may include a reader interface 306, and the reader interface 306 may communicate with the device reader 302 to receive measured physiological characteristics (that were communicated to the device reader 302 by one or more of the first device 100A or the second device 100B). In another example, the database and information processing system 304 may include a device interface 308. The device interface 308 may facilitate direct communication between the database and information processing system 304 and one or more of the first device 100 A and the second device 100B (e.g., the database and information processing system 304 may receive measured physiological characteristics from the first device 100A or the second device 100B; instead of receiving the measured physiological characteristics from the device reader 302). For instance, the device interface 308 may communicate with the device sensor interface 114 (of the device 100, shown in Figure 1) to facilitate reception of measured physiological characteristics by the database and information processing system 304.
[0031] The database and information processing system 304 may include memory circuitry 310. The memory circuitry 310 may store measured physiological characteristics. The system 300 may associate the measured physiological characteristics with a unique identifier associated with the first device 100 A (or the second device 100B), and the memory circuitry 310 may store the measured physiological characteristics associated with the unique identifier. For instance, the memory circuitry 310 may store a first set of measured physiological characteristics (measured by the first device 100A) and an associated first unique identifier (corresponding to the first device 100A). The memory circuitry 310 may store a second set of measured physiological characteristics (measured by the second device 100B) and an associated second unique identifier (corresponding to the second device 100B). Accordingly, the database and information processing system 304 may differentiate the first set of measured physiological characteristics from the second set of measured physiological characteristics. In another example, the database and information processing system 304 may include a processor 311, for instance the processor 311 may have processor circuitry. The system 300 may use one or more of the processor 311 or the memory circuitry 310, for instance to record data (e.g., measured physiological characteristics) in the memory circuitry 310. In yet another example, the database information processing system 304 may use one or more of the processor 311 or the memory circuitry 310, for instance to facilitate generation of a health status metric.
[0032] In another example, the database and information processing system 304 may associate the measured physiological characteristics with a time that the measured physiological characteristics were measured. For instance, a first set of measured physiological characteristics may be measured at a first time, and the memory circuitry 310 may store the first time in association with the first set of measured physiological characteristics. A second set of measured physiological characteristics may be measured at a second time, and the memory circuitry 310 may store the second time in association with the second set of measured physiological characteristics. Accordingly, the database and information processing system 304 may differentiate the first set of measured physiological characteristics from the second set of measured physiological characteristics. Thus, the system 300 may monitor physiological characteristics of a subject over one or more periods of time.
[0033] The system 300 may comply with provisions of the U.S. Health Insurance Portability and Accountability Act of 1996 (“HIPAA”). For instance, the system 300 may encrypt one or more of measured physiological characteristics or unique identifiers associated with the subject 200 (shown in Figure 2). In another example, the system 300 may anonymize the measured physiological characteristics, and only permit authorized users to deanonymize the measured physiological characteristics. In yet another example, the system 300 may only allow access to measured physiological data to authorized users. Accordingly, the system 300 maintains the privacy of the subject 200 (shown in Figure 2).
[0034] The database and information processing system 304 may include an information comparator 312. The information comparator 312 may compare physiological characteristics measured with the first device 100A or the second device 100B. For example, the information comparator 312 may compare a first set of measured physiological characteristics with a second set of measured physiological characteristics. The information comparator 312 may determine a difference between the first set of measured physiological characteristics and the second set of measured physiological characteristics, based on the comparison of the first set of measured physiological characteristics with the second set of measured physiological characteristics.
[0035] In an example, the first device 100 A may measure a first set of physiological characteristics at a first time (e.g., before treatment of a disease, or the like). The first device 100A may measure a second set of physiological characteristics at a second time (e.g., after one or more courses of treatment of a disease, or the like). The information comparator 312 may compare the first set of physiological characteristics with the second set of physiological characteristics, for instance to determine a difference between the first set of physiological characteristics and the second set of physiological characteristics. Accordingly, the information comparator 312 may determine the difference between measured physiological characteristics between the first time and the second time. In another example, the first device 100 A may measure a third set of physiological characteristics at a third time (e.g., after the second time). The information comparator may compare the third set of physiological characteristics with one or more of the first set of physiological characteristics or the second set of physiological characteristics. Thus, the information comparator 312 may determine the difference between measured physiological characteristics between the third time and one or more of the first time and the second time. The information comparator 312 may determine one or more rates of change of measured physiological characteristics. For instance, the information comparator 312 may determine a first rate of change between the first set of physiological characteristics and the second set of physiological characteristics. The information comparator 312 may determine a second rate of change between the third set of physiological characteristics and one or more of the first set of physiological characteristics or the second set of physiological characteristics. As a result, the system 300 monitors physiological characteristics of the subject 200 (shown in Figure 2), and changes to the physiological characteristics of the subject 200 (e.g., before, during, or after cessation of a course of treatment, or the like).
[0036] The database and information processing system 304 may include a health status metric generator 314. The health status metric generator 314 may generate a health status metric, for instance based on differences between measured physiological characteristics. The health status metric may correspond to efficacy of treatment for a disease. For instance, changes in measured physiological characteristics may correspond to a treatment being effective in treating a disease.
[0037] In an example, the health status metric may have a value of zero if the differences between measured physiological characteristics are not statistically significant. Statistical significance may be determined using, in one example, a statistical test, for example Welch’s t-test, or the like. For instance, the health status metric generator 314 may determine if a difference between the first set of physiological characteristics (measured at the first time) and the second set of physiological characteristics (measured at the second time) is statistically significant. The health status metric generator 314 may determine if a difference between the third set of physiological characteristics (measured at the third time) and one or more of the first or second sets of physiological characteristics is statistically significant. The health status metric may have a value of zero if the differences between measured sets of physiological characteristics are not statistically significant. The health status metric may have a value greater than zero if the differences between measured sets of physiological characteristics are statistically significant. For instance, magnitude of the health status metric may correspond with the degree of statistical significance of differences between measured sets of physiological characteristics. In another example, the magnitude of the health status metric may correspond with magnitude of differences between measured sets of physiological characteristics. For instance, an increase in the difference between measured sets of physiological characteristics may correspondingly increase the magnitude of the health status metric.
[0038] In another example, the health status metric may have a value of zero if the differences between measured physiological characteristics refrain from exceeding a difference threshold. For instance, the health status metric may have a value of zero if there is less than ten percent difference between sets of physiological characteristics measured by the system 300. Thus, in this example, the difference threshold corresponds to a difference of less than or equal to ten percent between the sets of physiological characteristics. The health status metric may have a value greater than zero if there is more than ten percent difference between the sets of physiological characteristics. The magnitude of the health status metric may correspond with a magnitude of differences between the sets of physiological characteristics. For instance, the health status metric may have a first value (greater than zero) in correspondence with a fifteen percent difference between the sets of physiological characteristics. The health status metric may have a second value (greater than the first value) in correspondence with a twenty percent difference between the sets of physiological characteristics. Accordingly, the health status metric may change based on changes in the measured physiological characteristics.
[0039] As described herein, the health status metric may correspond to efficacy of treatment for a disease. For instance, changes in measured physiological characteristics may correspond to a treatment being effective in treating a disease. In an example, a melanoma treated with adoptive T cell transfer immunotherapy may correspond with a decrease in one or more of body temperature (for instance measured at the control location 204, shown in Figure 2) or melanoma tissue temperature (for instance measured at the target location 202, shown in Figure 2). In another example, triple negative breast cancer treated with chemotherapy may correspond with a decline in temperature of the triple negative breast cancer tissue (for instance measured at the target location 202, shown in Figure 2). In yet another example, colon cancer treated with anti- PD-1 immunotherapy may correspond with a decrease in body temperature (for instance measured at the control location 204, shown in Figure 2). Accordingly, changes in measured physiological characteristics may correspond to a treatment being effective in treating a disease. Thus, the health status metric (generated by the health status metric generator 314) having a value greater than zero may indicate treatment given for a disease is effective. The changes in physiological characteristics may appear sooner than changes in physical characteristics (e.g., shape, size, color, or the like) of the abnormal tissue. As a result, the system 300 may expedite diagnosis of efficacy of treatment of the abnormal tissue.
[0040] Figure 4 shows a flowchart of a method 400 of using one or more human-implanted or animal-implanted devices (for instance the first device 100 A or the second device 100B, shown in Figures 2 and 3) for determining medical diagnostic information related to a course of treatment of a human or animal subject (for instance the subject 200, shown in Figure 2), for instance a subject having abnormal tissue (e.g., diseased tissue such as cancerous tissue, pre-cancerous tissue, or the like). In describing the method 400, reference is made to one or more components, features, functions and operations previously described herein. Where convenient, reference is made to the components, features, operations, and the like with reference numerals. The reference numerals provided are exemplary and are not exclusive. For instance, components, features, functions, operations, and the like described in the method 400 include, but are not limited to, the corresponding numbered elements provided herein and other corresponding elements described herein (both numbered and unnumbered) as well as their equivalents.
[0041] The method 400 may include measuring one or more physiological characteristics, for instance one or more of temperature, pH, oxygen, or glucose level. The measured one or more physiological characteristics may be received, for instance by components of the system 300 (shown in Figure 3). For example, the method 400 at 402 may include receiving a first set of one or more biological temperature measurements. The first set of one or more biological temperature measurements may be obtained from an implanted first device 100 A that includes a first temperature sensor (e.g., temperature sensor 106). The first device 100 A may be implanted at a target location 202 within the human or animal subject 200. The target location may include at least a portion of abnormal tissue, for instance cancerous tissue. At 404, the method 400 may include receiving a second set of one or more biological temperature measurements. The second set of one or more biological temperature measurements may be obtained from the implanted first device 100 A. The method 400 may include comparing the measured physiological characteristics, for instance comparing a first set of physiological characteristics with a second set of physiological characteristics. For example, the method 400 may include at 406, comparing the first set of temperature measurements with the second set of temperature measurements. For instance, an information comparator 312 may compare the first set of temperature measurements with the second set of temperature measurements. The comparison of the first set of temperature measurements with the second set of temperature measurements may occur at a first time. In another example, a first temperature differential measurement may be generated based on the comparison of the first set of temperature measurements with the second set of temperature measurements.
[0042] The method 400 may include generating a health status metric. In an example, the health status metric may be generated using the measured physiological characteristics. The health status metric may be generated based on comparison of the measured physiological characteristics. The health status metric may be generated based on measurements from two or more of the sensors 102. For example, the health status metric may be generated based on two or more of the temperature measurements, pH measurements, oxygen measurements, or glucose level measurements produced by the sensors 102. For example, at 408, the method 400 may include using the first temperature differential measurement, for instance to generate a health status metric of the subject. In an example, a health status metric generator 314 generates the health status metric.
[0043] Several options for the method 400 follow. The method 400 may include administration of a course of treatment to the subject 200. In an example, the course of treatment includes administration of one or more of a first dose of treatment or a second dose of treatment. For example, the first dose of treatment may include a first administration of chemotherapy. The second dose may include a second administration of the chemotherapy. The second dose may include a different form of treatment, for example immunotherapy.
[0044] The medical diagnostic information related to a course of treatment may include measured physiological characteristics. For example, the method 400 may include measurement of physiological characteristics prior to initiation of the course of treatment (e.g., before administration of a first dose of treatment, for instance a first dose of chemotherapy). In an example, the physiological characteristics of the subject 200 are measured an hour before, a day before, a week before, or a month before initiation of a course of treatment (or at times therebetween).
[0045] The method 400 may include measurement of physiological characteristics during the course of treatment. Stated another way, the physiological characteristics of the subject 200 may be measured after initiation of the course of treatment. In another example, the physiological characteristics of the subject may be measured concurrently with the course of treatment. For example, the physiological characteristics of the subject 200 may be measured after administration of a first dose of treatment, for instance a first dose of immunotherapy. In another example, the physiological characteristics of the subject 200 may be measured after administration of a second dose of treatment, for instance a second dose of immunotherapy (or another form of treatment). The physiological characteristics of the subject 200 may be measured concurrently with the first dose of treatment, an hour after the first dose of treatment, a day after the first dose of treatment, a month after the first dose of treatment, or the like (or at times therebetween). The physiological characteristics of the subject 200 may be measured concurrently with the second dose of treatment, an hour after the second dose of treatment, a day after the second dose of treatment, a month after the second dose of treatment, or the like. Accordingly, physiological characteristics of the subject may be measured during a course of treatment.
[0046] The physiological characteristics may be measured after cessation of the course of treatment. For instance, the physiological characteristics of the subject 200 may be measured after a (planned) final dose of treatment, for example a final dose of chemotherapy. In another example, the physiological characteristics of the subject 200 may be measured after a determination that a disease has been cured, for instance after a determination cancer has entered remission. The physiological characteristics of the subject 200 may be measured an hour after the cessation of the course of treatment, a day after the cessation of the course of treatment, a month after the cessation of the course of treatment, or the like (or at times therebetween). In yet another example, the physiological characteristics of the subject 200 are measured indefinitely after the course of treatment (e.g. months after cessation of the course of treatment, years after the course of treatment, or the like). For instance, the physiological characteristics of the subject are monitored to determine if there is a recurrence in cancer or intensification of disease. Accordingly, the physiological characteristics of the subject may be measured in relation to a course of treatment (e.g., prior to, during, or after cessation of the course of treatment). Thus, a health status metric may be generated in relation to a course of treatment (e.g., prior to, during, or after cessation of the course of treatment). In another example, physiological characteristics of the subject may be measured repeatedly in relation to the course of treatment (e.g., in two or more instances, or the like). The health status metric may be generated repeatedly in relation to a course of treatment (e.g., in two or more instances, or the like).
[0047] In another example, the method 400 may include receiving a third set of one or more biological temperature measurements. In an example, the third set of one or more biological temperature measurements may be obtained from a second device 100B that includes a second temperature sensor (for instance the temperature sensor 106). The second device 100B may be implanted at a control location 204 that is different from the target location 202. The method 400 may include comparing the first set of temperature measurements with the third set of temperature measurements at a second time. A second temperature differential measurement may be generated based on the comparison of the first set of temperature measurements with the third set of temperature measurements. The comparison of the first set of temperature measurements with the third set of temperature measurements may occur at a second time. In another example, the method 400 may include generating the health status metric of the subject 200, for instance using the first and second temperature differential measurements.
[0048] In yet another example, the method 400 may include identifying a difference between the first and second temperature differential measurements. The difference between the first and second temperature differential measurements may be used to generate the health status metric of the subject 200. In still yet another example, the method 400 may include treating the subject 200. The treatment may include one or more of immunotherapy, chemotherapy, or radiation therapy. In a further example, the method 400 may include implanting the first device 100A at the target location 202 within the subject 200. In a still further example, the method 400 may include implanting the second device 100B at the control location 204 within the subject 200. In a still yet further example, the method 400 may include receiving one or more of a first pH value, a first oxygen value, or a first glucose value. One or more of a second pH value, a second oxygen value, or a second glucose value may be received, for instance by a device reader 302. The first pH value, second pH value, first oxygen value, second oxygen value, first glucose value, or the second glucose value may be obtained from one or more of a pH sensor 108, an oxygen sensor 110, or a glucose level sensor 112.
[0049] The method 400 may include comparing the first pH value with the second pH value, for instance to generate a first pH differential measurement. In an example, the information comparator 312 may compare the first pH value with the second pH value. The information comparator 312 may generate the first pH differential measurement. The health status metric of the subject 200 may be generated using the first pH differential measurement. The method 400 may include comparing the first oxygen value with the second oxygen value, for instance to generate a first oxygen differential measurement. In an example, the information comparator 312 may compare the first oxygen value with the second oxygen value. The information comparator 312 may generate the first oxygen differential measurement. The health status metric of the subject 200 may be generated using the first oxygen differential measurement. The method 400 may include comparing the first glucose value with the second glucose value, for instance to generate a first glucose differential measurement. In an example, the information comparator 312 may compare the first glucose value with the second glucose value. The information comparator 312 may generate the first glucose differential measurement. The health status metric of the subject 200 may be generated using the first glucose differential measurement.
[0050] The method 400 may include that the health status metric includes an indication of whether the course of treatment is effective in treating the abnormal tissue, for instance cancerous tissue, of the subject 200. For instance, the indication may be a value of zero corresponding to the treatment being ineffective in treating the cancerous tissue of the subject 200. The indication may be a value greater than zero corresponding to the treatment being effective in treating the cancerous tissue of the subject 200.
[0051] The course of treatment may be continued based on the indication of whether the course of treatment is effective in treating the abnormal tissue of the subject 200. For instance, the course of treatment may be continued if the treatment is effective. In another example, additional sets of measured physiological characteristics are measured after continuing the course of treatment of the subject 200. For example, a first dose of treatment in the course of treatment is administered to the subject 200. In some examples, the first dose of treatment in the course of treatment may be determined to be effective, for instance using the health status metric. In another example, the first dose of treatment may be determined to be ineffective, for instance using the health status metric. A second dose in the course of treatment may be administered to the subject 200. The second dose may be indicated to be effective, for instance by measuring one or more physiological characteristics after the second dose is administered, and generating the health status metric based on the physiological characteristics measured after the second dose is administered. Accordingly, efficacy of the course of treatment is monitored, for instance using one or more components of the system 300.
[0052] The course of treatment may be discontinued based on the indication of whether the course of treatment is effective in treating the abnormal tissue of the subject 200. For instance, the course of treatment may be discontinued if the course of treatment is determined to be ineffective, for instance using the health status metric. In yet another example, the course of treatment may be changed based on the indication of whether the course of treatment is effective in treating the abnormal tissue of the subject. For instance, a first dose in the course of treatment may be administered to the subject 200. An amount (e.g., volume, concentration, duration, or the like) of treatment may be changed based on the indication of whether the course of treatment is effective in treating the abnormal tissue of the subject 200 (e.g., by increasing the amount of treatment given to the patient, for instance by doubling the amount of the first dose). The course of treatment may be changed to provide a different treatment. For instance, the first dose in the course of treatment may use chemotherapy. A second dose in the course of treatment may be administered to the patient. The second dose may include immunotherapy. Accordingly, the treatment is changed during the course of treatment, for instance if the first dose is determined to be ineffective or the first dose is determined to be effective and the second dose enhances effectiveness of the first dose.
[0053] Figure 5 shows a flowchart of an example of a computer-implemented method 500 for monitoring a subject of a medical treatment. In describing the method 500, reference is made to one or more components, features, functions and operations previously described herein. Where convenient, reference is made to the components, features, operations, and the like with reference numerals. The reference numerals provided are exemplary and are not exclusive. For instance, components, features, functions, operations, and the like described in the method 500 include, but are not limited to, the corresponding numbered elements provided herein and other corresponding elements described herein (both numbered and unnumbered) as well as their equivalents.
[0054] The method 500 may include at 502, storing an identifier for the subject 200 in a database in memory circuitry 310 of a computing device (e.g., the database and information processing system 304, shown in Figure 3). At 504, the method 500 may include storing an identifier for a temperature sensor (e.g., temperature sensor 106, shown in Figure 1) enabled implantable device 100 implanted within the subject 200 in the database in memory circuitry 310 of the computing device. The identifier for the temperature sensor may be stored in association with the stored identifier for the subject 200.
[0055] Several options for the method 500 follow. For example, the method 500 may include storing, in the database, a first set of temperature measurements obtained from the implantable device 100. In another example, the method 500 may include storing, in the database, treatment information related to the subject 200. In yet another example, the method 500 may include storing, in the database, information related to implantation of the device 100 within the subject 200, for example one or more of location or orientation of the device 100 implanted within the subject 200. In still yet another example, the method 500 may include storing, in the database, information related to the subject 200, for example one or more of abnormal body tissue (e.g., diseased tissue, cancerous tissue, pre-cancerous tissue, or the like) or pathologies present with the subject 200. One or more of the first set of temperature measurements, the identifier for the subject 200, the identifier for the temperature sensor, the treatment information related to the subject 200, the information related to implantation of the device 100, or information related to one or more of abnormal body tissue or pathologies present with the subject 200 may be stored in a manner to comply with HIPAA.
[0056] Figure 6 shows a schematic diagram of another example of the system 300. The system 300 may include the health status metric generator 314. The health status metric generator 314 may include a machine learning algorithm. The machine learning algorithm may include one or more of a supervised, semisupervised, unsupervised, or reinforcement algorithm. For example, the machine learning algorithm may include a classifier, for instance an Artificial Neural Network, Support Vector Machine, K-Nearest Neighbor, or the like. The health status metric generator 314 may use the machine learning algorithm to determine the health status metric.
[0057] In an example, the health status metric generator 314 may include machine learning model training 600. The machine learning model training 600 may generate a trained machine learning model 602. For instance, the machine learning model training 600 may receive training data 604. The reception of the training data 604 by the machine learning model training 600 may generate the trained machine learning model 602.
[0058] In an example, the training data 604 includes one or more physiological characteristics 606. For instance, the sensors 102 (shown in Figure 1) may measure the one or more physiological characteristics 606. The training data 604 may include the measured one or more physiological characteristics 606. In an example, the physiological characteristics 606 include one or more of temperature, pH, oxygen, or glucose value (or combinations thereof, or the like).
[0059] The training data 604 may include treatment type 608. For example, a user may input the treatment type 608 into the training data 604. The treatment type 608 may be associated with the measured physiological characteristics 606. For instance, a first set of one or more physiological characteristics may be associated with a first course of treatment. A second set of one or more physiological characteristics may be associated with a second course of treatment. The training data 604 may include disease type 610, and the disease type 610 may include one or more diseases. For example, a user may input the disease type 610 into the training data 604. In an example, the disease type 610 may include one or more types of cancer. The disease type 610 may include metastasized cancer. The disease type 610 may include diseases other than cancer, for instance an infection. In some examples, the disease type 610 does not include infection. In another example, the disease type 610 may include an autoimmune disease. In yet another example, the disease type 610 may be associated with one or more of the treatment type 608 or the measured physiological characteristics 606. For instance, a first set of one or more physiological characteristics may be associated with a first course of treatment and a first disease type. A second set of one or more physiological characteristics may be associated with a second course of treatment and the first disease type (or a second disease type). Accordingly, the physiological characteristics 606 may be correlated with one or more of the treatment type 608 or the disease type 610.
[0060] The training data 604 may include treatment efficacy 612. For example, a user may input the treatment efficacy 612 into the training data 604. The treatment efficacy 612 may correspond with efficacy of a course of treatment in treating a disease. In an example, the treatment efficacy 612 may be positive and correspond with a complete remission of cancer in a subject, for instance the subject 200 (shown in Figure 2). For example, the treatment efficacy 612 may be positive and correspond with elimination of tumors detected with medical imaging or other medical tests, such as a blood test. In another example, the treatment efficacy 612 may be positive and correspond with a partial remission of the cancer. For instance, the treatment efficacy 612 may be positive and correspond with partial elimination of tumors detected with imaging or other tests. In another example, the treatment efficacy 612 may be positive and correspond with a decrease in size of cancerous tissue (e.g., a decrease in size of a tumor, or the like). In yet another example, the treatment efficacy 612 may be positive and correspond with maintaining size of cancerous tissue (e.g., a tumor does not increase in size or decrease in size, or the like). In still yet another example, the treatment efficacy 612 may be negative and correspond with maintaining size of cancerous tissue. In a further example, the treatment efficacy 612 may be negative and correspond with an increase in size of cancerous tissue (or an increase in cancer markers in a blood test, or the like). Accordingly, the treatment efficacy may be positive or negative, based on changes (or lack of changes) in physical size of cancerous tissue.
[0061] In another example, the treatment efficacy 612 may be associated with one or more of the treatment type 608, the measured physiological characteristics 606, or the disease type 610. For instance, a first set of one or more physiological characteristics may be associated with a first course of treatment, a first disease type, and a first treatment efficacy. A second set of one or more physiological characteristics may be associated with a second course of treatment, the first disease type (or a second disease type), and a second treatment efficacy. Accordingly, the physiological characteristics 606 may be correlated with one or more of the treatment type 608, the disease type 610, or the treatment efficacy 612.
[0062] As described herein, the reception of the training data 604 by the machine learning model training 600 may generate the trained machine learning model 602. The trained machine learning model 602 may use new data 614, for instance to generate health status metric 616. For example, the trained machine learning model 602 may use the new data 614 in combination with a (trained) machine learning algorithm to generate the health status metric 616. For instance, the health status metric 616 may correspond with efficacy of treatment (e.g., positive, negative, a value of zero, a value greater than zero, or the like).
[0063] In an example, the new data 614 may include one or more physiological characteristics 606, for instance physiological characteristics 606 measured from the subject 200 (shown in Figure 2). In contrast, the training data 604 may use the physiological characteristics 606 of a plurality of training subjects (in some examples excluding the subject 200). In another example, the new data 614 may include treatment type 608, for instance one or more doses of chemotherapy administered to the subject 200. In contrast, the training data 604 may use the treatment type 608 of a plurality of training subjects (in some examples excluding the subject 200). In yet another example, the new data 614 may include disease type 610, for instance a type of cancer afflicting the subject 200. In contrast, the training data 604 may use the disease type 610 of a plurality of training subjects (in some examples excluding the subject 200). Accordingly, the health status metric 616 may be based on one or more of the physiological characteristics 606 measured with respect to the subject 200, the treatment type 608 associated with the subject 200, or the disease type 610 associated with the subject.
[0064] The health status metric 616 may correspond with efficacy of treatment (e.g., positive, negative, a value of zero, a value greater than zero, or the like). The health status metric 616 may facilitate differentiation between an infection response and a response of cancer to treatment. For instance, the training data 604 may include one or more of physiological characteristics 606 corresponding with presence of an infection in a subject (or plurality of subjects). The training data 604 may include one or more physiological characteristics 606 corresponding with presence of cancer in a subject (or a plurality of subjects). The training data 604 may include one or more physiological characteristics corresponding with presence of an autoimmune disease in a subject (or a plurality of subjects). The training data 604 may include one or more physiological characteristics corresponding with a healthy (non-diseased) subject (or plurality of subjects). Accordingly, the trained machine learning model 602 may use the training data 604 to differentiate between a healthy subject, a subject afflicted with cancer, a subject experiencing infection, or a subject afflicted with an autoimmune disease. In another example, the system 300 facilitates monitoring of efficacy of a course of treatment administered to the subject 200. As a result, treatment of disease is enhanced, for instance because the device 100 (or the system 300) may facilitate determining whether a particular course of treatment is effective in treatment of the disease (or whether a response is related to infection, autoimmune disease, or the like).
[0065] Figure 7 shows a block diagram of an example machine 700 upon which any one or more of the techniques (e.g., methodologies, methods, operations, or the like) discussed herein may perform. Examples, as described herein, may include, or may operate by, logic or a number of components, or mechanisms in the machine 700. Circuitry (e.g., processing circuitry) is a collection of circuits implemented in tangible entities of the machine 700 that include hardware (e.g., simple circuits, gates, logic, etc.). Circuitry membership may be flexible over time. Circuitries include members that may, alone or in combination, perform specified operations when operating. In an example, hardware of the circuitry may be immutably designed to carry out a specific operation (e.g., hardwired). In an example, the hardware of the circuitry may include variably connected physical components (e.g., execution units, transistors, simple circuits, etc.) including a machine readable medium physically modified (e.g., magnetically, electrically, moveable placement of invariant massed particles, etc.) to encode instructions of the specific operation. In connecting the physical components, the underlying electrical properties of a hardware constituent are changed, for example, from an insulator to a conductor or vice versa. The instructions enable embedded hardware (e.g., the execution units or a loading mechanism) to create members of the circuitry in hardware via the variable connections to carry out portions of the specific operation when in operation. Accordingly, in an example, the machine readable medium elements are part of the circuitry or are communicatively coupled to the other components of the circuitry when the device is operating. In an example, any of the physical components may be used in more than one member of more than one circuitry. For example, under operation, execution units may be used in a first circuit of a first circuitry at one point in time and reused by a second circuit in the first circuitry, or by a third circuit in a second circuitry at a different time. Additional examples of these components with respect to the machine 700 follow.
[0066] In alternative embodiments, the machine 700 may operate as a standalone device or may be connected (e.g., networked) to other machines. In a networked deployment, the machine 700 may operate in the capacity of a server machine, a client machine, or both in server-client network environments. In an example, the machine 700 may act as a peer machine in peer-to-peer (P2P) (or other distributed) network environment. The machine 700 may be a personal computer (PC), a tablet PC, a set-top box (STB), a personal digital assistant (PDA), a mobile telephone, a web appliance, a network router, switch or bridge, or any machine capable of executing instructions (sequential or otherwise) that specify actions to be taken by that machine. Further, while only a single machine is illustrated, the term “machine” shall also be taken to include any collection of machines that individually or jointly execute a set (or multiple sets) of instructions to perform any one or more of the methodologies discussed herein, such as cloud computing, software as a service (SaaS), other computer cluster configurations. The machine (e.g., computer system) 700 may include a hardware processor 702 (e.g., a central processing unit (CPU), a graphics processing unit (GPU), a hardware processor core, or any combination thereof), a main memory 704, a static memory (e.g., memory or storage for firmware, microcode, a basic- input-output (BIOS), unified extensible firmware interface (UEFI), etc.) 706, and mass storage 708 (e.g., hard drive, tape drive, flash storage, or other block devices) some or all of which may communicate with each other via an interlink (e.g., bus) 730. The machine 700 may further include a display unit 710, an alphanumeric input device 712 (e.g., a keyboard), and a user interface (UI) navigation device 714 (e.g., a mouse). In an example, the display unit 710, input device 712 and UI navigation device 714 may be a touch screen display. The machine 700 may additionally include a storage device (e.g., drive unit) 708, a signal generation device 718 (e.g., a speaker), a network interface device 720, and one or more sensors 716, such as a global positioning system (GPS) sensor, compass, accelerometer, or other sensor. The machine 700 may include an output controller 728, such as a serial (e.g., universal serial bus (USB), parallel, or other wired or wireless (e.g., infrared (IR), near field communication (NFC), etc.) connection to communicate or control one or more peripheral devices (e.g., a printer, card reader, etc.).
[0067] Registers of the processor 702, the main memory 704, the static memory 706, or the mass storage 708 may be, or include, a machine readable medium 722 on which is stored one or more sets of data structures or instructions 724 (e.g., software) embodying or utilized by any one or more of the techniques or functions described herein. The instructions 724 may also reside, completely or at least partially, within any of registers of the processor 702, the main memory 704, the static memory 706, or the mass storage 708 during execution thereof by the machine 700. In an example, one or any combination of the hardware processor 702, the main memory 704, the static memory 706, or the mass storage 708 may constitute the machine readable media 722. While the machine readable medium 722 is illustrated as a single medium, the term "machine readable medium" may include a single medium or multiple media (e.g., a centralized or distributed database, and / or associated caches and servers) configured to store the one or more instructions 724. The term “machine readable medium” may include any medium that is capable of storing, encoding, or carrying instructions for execution by the machine 700 and that cause the machine 700 to perform any one or more of the techniques of the present disclosure, or that is capable of storing, encoding or carrying data structures used by or associated with such instructions. Nonlimiting machine readable medium examples may include solid-state memories, optical media, magnetic media, and signals (e.g., radio frequency signals, other photon based signals, sound signals, etc.). In an example, a non-transitory machine readable medium comprises a machine readable medium with a plurality of particles having invariant (e.g., rest) mass, and thus are compositions of matter. Accordingly, non-transitory machine-readable media are machine readable media that do not include transitory propagating signals. Specific examples of non-transitory machine readable media may include: non-volatile memory, such as semiconductor memory devices (e.g., Electrically Programmable Read-Only Memory (EPROM), Electrically Erasable Programmable Read-Only Memory (EEPROM)) and flash memory devices; magnetic disks, such as internal hard disks and removable disks; magnetooptical disks; and CD-ROM and DVD-ROM disks.
[0068] The instructions 724 may be further transmitted or received over a communications network 726 using a transmission medium via the network interface device 720 utilizing any one of a number of transfer protocols (e.g., frame relay, internet protocol (IP), transmission control protocol (TCP), user datagram protocol (UDP), hypertext transfer protocol (HTTP), etc.). Example communication networks may include a local area network (LAN), a wide area network (WAN), a packet data network (e.g., the Internet), mobile telephone networks (e.g., cellular networks), Plain Old Telephone (POTS) networks, and wireless data networks (e.g., Institute of Electrical and Electronics Engineers (IEEE) 802.11 family of standards known as Wi-Fi®, IEEE 802.16 family of standards known as WiMax®), IEEE 802.11.4 family of standards, peer-to-peer (P2P) networks, among others. In an example, the network interface device 720 may include one or more physical jacks (e.g., Ethernet, coaxial, or phonejacks) or one or more antennas to connect to the communications network 726. In an example, the network interface device 720 may include a plurality of antennas to wirelessly communicate using at least one of single-input multiple-output (SIMO), multiple-input multiple-output (MIMO), or multiple-input single-output (MISO) techniques. The term “transmission medium” shall be taken to include any intangible medium that is capable of storing, encoding or carrying instructions for execution by the machine 700, and includes digital or analog communications signals or other intangible medium to facilitate communication of such software. A transmission medium is a machine readable medium.
[0069] Various Notes & Aspects
[0070] Example l is a method of using one or more human-implanted or animal- implanted oncology monitoring devices for determining medical diagnostic information related to a course of treatment of a human or animal subject having a cancerous tissue, the method comprising: receiving a first set of one or more biological temperature measurements, obtained from an implanted first oncology monitoring device that includes a first temperature sensor, wherein the first oncology monitoring device is implanted at a target location within the human or animal subject, the target location including at least a portion of the cancerous tissue; receiving a second set of one or more biological temperature measurements, obtained from the implanted first oncology monitoring device; comparing the first set of temperature measurements with the second set of temperature measurements at a first time to generate a first temperature differential measurement; and using at least the first temperature differential measurement, generating a health status metric of the subject.
[0071] In Example 2, the subject matter of Example 1 optionally includes receiving a third set of one or more biological temperature measurements, obtained from a second oncology monitoring device that includes a second temperature sensor, wherein the second oncology monitoring device is implanted at a control location that is different from the target location; comparing the first set of temperature measurements with the third set of temperature measurements at a second time to generate a second temperature differential measurement; and generating the health status metric of the subject includes using the first and second temperature differential measurements. In Example 3, the subject matter of Example 2 optionally includes identifying a difference between the first and second temperature differential measurements; and generating the health status metric of the subject includes using the difference between the first and second temperature differential measurements.
[0072] In Example 4, the subject matter of any one or more of Examples 1-3 optionally include wherein the course of treatment includes one or more of immunotherapy, chemotherapy, or radiation therapy.
[0073] In Example 5, the subject matter of any one or more of Examples 1-4 optionally include wherein the course of treatment includes administration of two or more doses of treatment.
[0074] In Example 6, the subject matter of Example 5 optionally includes wherein the course of treatment includes a first dose administered to the subject and a second dose administered to the subject after the first dose.
[0075] In Example 7, the subject matter of Example 6 optionally includes wherein the first set of one or more biological measurements are received prior to the first dose, and the second set of one or more biological temperature measurements are received after the first dose and prior to the second dose.
[0076] In Example 8, the subject matter of Example 7 optionally includes wherein: the method includes receiving a third set of one or more biological temperature measurements obtained from the implanted first oncology monitoring device; and the third set of one or more biological temperature measurements are received after the second dose given to the subject.
[0077] In Example 9, the subject matter of any one or more of Examples 6-8 optionally include wherein the first set of one or more biological measurements are received prior to administration of the second dose, and the second set of one or more biological temperature measurements are received after the second dose.
[0078] In Example 10, the subject matter of any one or more of Examples 1-9 optionally include wherein the first set of one or more biological measurements are received prior to the course of treatment, and the second set of one or more biological temperature measurements are received before the course of treatment.
[0079] In Example 11, the subject matter of any one or more of Examples 1-10 optionally include wherein the first set of one or more biological temperature measurements are received after the course of treatment, and the second set of one or more biological temperature measurements are received during the course of treatment.
[0080] In Example 12, the subject matter of any one or more of Examples 1-11 optionally include wherein one or more of the first set of one more biological temperature measurements or the second set of one or more biological temperature measurements are received after cessation of the course of treatment 12 is missing parent: 13. The method of Example 1, further comprising implanting the first oncology monitoring device at the target location within the subject.
[0081] In Example 13, the subject matter of Example undefined optionally includes , further comprising implanting a second oncology monitoring device having a second temperature sensor at the control location within the subject.
[0082] In Example 14, the subject matter of any one or more of Examples 1-13 optionally include wherein: the first oncology monitoring device includes one or more of a pH sensor, an oxygen sensor, or a glucose sensor; the method includes receiving one or more of a first pH value, a first oxygen value, or a first glucose value, obtained from one or more of the pH sensor, the oxygen sensor, or the glucose level sensor; and the method includes receiving one or more of a second pH value, a second oxygen value, or a second glucose value, obtained from one or more of the pH sensor, the oxygen sensor, or the glucose level sensor.
[0083] In Example 15, the subject matter of Example 14 optionally includes comparing the first pH value with the second pH value to generate a first pH differential measurement; and generating the health status metric of the subject includes using the first pH differential measurement and the first temperature differential measurement.
[0084] In Example 16, the subject matter of any one or more of Examples 14-15 optionally include comparing the first oxygen value with the second oxygen value to generate a first oxygen differential measurement; and generating the health status metric of the subject includes using the first oxygen differential measurement and the first temperature differential measurement.
[0085] In Example 17, the subject matter of any one or more of Examples 14-16 optionally include comparing the first glucose value with the second glucose value to generate a first glucose differential measurement; and generating the health status metric of the subject includes using the first glucose differential measurement.
[0086] In Example 18, the subject matter of any one or more of Examples 1-17 optionally include wherein a health status metric generator includes a machine learning algorithm trained with one or more measured physiological characteristics from a plurality of training subjects where the course of treatment was effective in treating the plurality of treated subjects.
[0087] In Example 19, the subject matter of Example 18 optionally includes wherein the health status metric generator uses the machine learning algorithm to generate the health status metric.
[0088] In Example 20, the subject matter of any one or more of Examples 18-19 optionally include wherein the machine learning algorithm is trained with a combination of measured physiological characteristics, from the plurality of training subjects where the course of treatment was effective in treating the plurality of training subjects, including two or more of temperature, pH, oxygen, or glucose.
[0089] In Example 21, the subject matter of any one or more of Examples 18-20 optionally include wherein the health status metric includes an indication of whether the course of treatment is effective in treating the cancerous tissue of the subject.
[0090] In Example 22, the subject matter of any one or more of Examples 1-21 optionally include wherein the health status metric includes an indication of whether the course of treatment is effective in treating the cancerous tissue of the subject.
[0091] In Example 23, the subject matter of any one or more of Examples 21-22 optionally include continuing the course of treatment based on the indication of whether the course of treatment is effective in treating the cancerous tissue of the subject.
[0092] In Example 24, the subject matter of any one or more of Examples 21-23 optionally include discontinuing the course of treatment based on the indication of whether the course of treatment is effective in treating the cancerous tissue of the subject.
[0093] In Example 25, the subject matter of any one or more of Examples 21-24 optionally include changing the course of treatment based on the indication of whether the course of treatment is effective in treating the cancerous tissue of the subject.
[0094] Example 26 is a computer-implemented method for monitoring a subject of an oncology medical treatment, the method comprising: storing an identifier for the subject in a database in memory circuitry of a computing device; and storing an identifier for a temperature sensor enabled implantable oncology monitoring device implanted within the subject in the database in memory circuitry of the computing device, in association with the stored identifier for the subject.
[0095] In Example 27, the subject matter of Example 26 optionally includes storing, in the database, a first set of temperature measurements obtained from the implantable oncology monitoring device.
[0096] In Example 28, the subject matter of any one or more of Examples 26-27 optionally include storing, in the database, treatment information related to the subject.
[0097] In Example 29, the subject matter of any one or more of Examples 26-28 optionally include storing, in the database, information related to implantation of the oncology monitoring device within the subject including one or more of location or orientation of the device implanted within the subject.
[0098] In Example 30, the subject matter of any one or more of Examples 26-29 optionally include storing, in the database, information related to the subject, including one or more of abnormal body tissue or pathologies present with the subject.
[0099] In Example 31, the subject matter of any one or more of Examples 26-30 optionally include wherein at least the identifier for the subject and the identifier for the temperature sensor are stored in a manner to comply with at least HIPAA.
[0100] Example 32 is a system for monitoring one or more physiological characteristics of a human or animal subject, the system comprising: a first oncology monitoring device configured to measure at least a first set of one or more physiological parameters at a first time and a second set of one or more physiological parameters at a second time, wherein: the first time is prior to, or concurrent with, treatment provided to the subject; the second time is after treatment provided to the subject; and the first oncology monitoring device is configured for implantation in the subject; and a database and information processing system, including: a device interface configured for communication with the first oncology monitoring device, wherein the device interface is configured to receive measured first and second sets of one or more physiological parameters; memory circuitry configured to store at least the first and second sets of one or more physiological parameters; an information comparator configured to compare the first set of physiological characteristics with the second set of physiological characteristics; and a health status metric generator configured to generate a health status metric based on the comparison of the first set of physiological characteristics with the second set of physiological characteristics, wherein the health status metric corresponds with efficacy of treatment provided to the subject.
[0101] In Example 33, the subject matter of Example 32 optionally includes a second oncology monitoring device configured to measure at least a third set of one or more physiological parameters at one or more of the first time or the second time, wherein the second device is configured for implantation in the subject.
[0102] Each of these non-limiting examples can stand on its own, or can be combined in various permutations or combinations with one or more of the other examples (or portions thereof).
[0103] The above description includes references to the accompanying drawings, which form a part of the detailed description. The drawings show, by way of illustration, specific embodiments in which the invention can be practiced. These embodiments are also referred to herein as “examples.” Such examples can include elements in addition to those shown or described. However, the present inventors also contemplate examples in which only those elements shown or described are provided. Moreover, the present inventors also contemplate examples using any combination or permutation of those elements shown or described (or one or more aspects thereof), either with respect to a particular example (or one or more aspects thereof), or with respect to other examples (or one or more aspects thereof) shown or described herein.
[0104] In the event of inconsistent usages between this document and any documents so incorporated by reference, the usage in this document controls. In this document, the terms “a” or “an” are used, as is common in patent documents, to include one or more than one, independent of any other instances or usages of “at least one” or “one or more.” In this document, the term “or” is used to refer to a nonexclusive or, such that “A or B” includes “A but not B,” “B but not A,” and “A and B,” unless otherwise indicated. In this document, the terms “including” and “in which” are used as the plain-English equivalents of the respective terms “comprising” and “wherein.” Also, in the following claims, the terms “including” and “comprising” are open-ended, that is, a system, device, article, composition, formulation, or process that includes elements in addition to those listed after such a term in a claim are still deemed to fall within the scope of that claim. Moreover, in the following claims, the terms “first,” “second,” and “third,” etc. are used merely as labels, and are not intended to impose numerical requirements on their objects.
[0105] Geometric terms, such as “parallel”, “perpendicular”, “round”, or “square”, are not intended to require absolute mathematical precision, unless the context indicates otherwise. Instead, such geometric terms allow for variations due to manufacturing or equivalent functions. For example, if an element is described as “round” or “generally round,” a component that is not precisely circular (e.g., one that is slightly oblong or is a many-sided polygon) is still encompassed by this description.
[0106] Method examples described herein can be machine or computer- implemented at least in part. Some examples can include a computer-readable medium or machine-readable medium encoded with instructions operable to configure an electronic device to perform methods as described in the above examples. An implementation of such methods can include code, such as microcode, assembly language code, a higher-level language code, or the like. Such code can include computer readable instructions for performing various methods. The code may form portions of computer program products. Further, in an example, the code can be tangibly stored on one or more volatile, non- transitory, or non-volatile tangible computer-readable media, such as during execution or at other times. Examples of these tangible computer-readable media can include, but are not limited to, hard disks, removable magnetic disks, removable optical disks (e.g., compact disks and digital video disks), magnetic cassettes, memory cards or sticks, random access memories (RAMs), read only memories (ROMs), and the like.
[0107] The above description is intended to be illustrative, and not restrictive. For example, the above-described examples (or one or more aspects thereof) may be used in combination with each other. Other embodiments can be used, such as by one of ordinary skill in the art upon reviewing the above description. The Abstract is provided to comply with 37 C.F.R. § 1.72(b), to allow the reader to quickly ascertain the nature of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims. Also, in the above Detailed Description, various features may be grouped together to streamline the disclosure. This should not be interpreted as intending that an unclaimed disclosed feature is essential to any claim. Rather, inventive subject matter may lie in less than all features of a particular disclosed embodiment. Thus, the following claims are hereby incorporated into the Detailed Description as examples or embodiments, with each claim standing on its own as a separate embodiment, and it is contemplated that such embodiments can be combined with each other in various combinations or permutations. The scope of the invention should be determined with reference to the appended claims, along with the full scope of equivalents to which such claims are entitled.
Claims
WHAT IS CLAIMED IS:
1. A method of using one or more human-implanted or animal -implanted oncology monitoring devices for determining medical diagnostic information related to a course of treatment of a human or animal subject having a cancerous tissue, the method comprising: receiving a first set of one or more biological temperature measurements, obtained from an implanted first oncology monitoring device that includes a first temperature sensor, wherein the first oncology monitoring device is implanted at a target location within the human or animal subject, the target location including at least a portion of the cancerous tissue; receiving a second set of one or more biological temperature measurements, obtained from the implanted first oncology monitoring device; comparing the first set of temperature measurements with the second set of temperature measurements at a first time to generate a first temperature differential measurement; and using at least the first temperature differential measurement, generating a health status metric of the subject.
2. The method of claim 1, further comprising: receiving a third set of one or more biological temperature measurements, obtained from a second oncology monitoring device that includes a second temperature sensor, wherein the second oncology monitoring device is implanted at a control location that is different from the target location; comparing the first set of temperature measurements with the third set of temperature measurements at a second time to generate a second temperature differential measurement; and generating the health status metric of the subject includes using the first and second temperature differential measurements.
3. The method of claim 2, further comprising: identifying a difference between the first and second temperature differential measurements; andgenerating the health status metric of the subject includes using the difference between the first and second temperature differential measurements.
4. The method of claim 1, wherein the course of treatment includes one or more of immunotherapy, chemotherapy, or radiation therapy.
5. The method of claim 1, wherein the course of treatment includes administration of two or more doses of treatment.
6. The method of claim 5, wherein the course of treatment includes a first dose administered to the subject and a second dose administered to the subject after the first dose.
7. The method of claim 6, wherein the first set of one or more biological measurements are received prior to the first dose, and the second set of one or more biological temperature measurements are received after the first dose and prior to the second dose.
8. The method of claim 7, wherein: the method includes receiving a third set of one or more biological temperature measurements obtained from the implanted first oncology monitoring device; and the third set of one or more biological temperature measurements are received after the second dose given to the subject.
9. The method of claim 6, wherein the first set of one or more biological measurements are received prior to administration of the second dose, and the second set of one or more biological temperature measurements are received after the second dose.
10. The method of claim 1, wherein the first set of one or more biological measurements are received prior to the course of treatment, and the second set of one or more biological temperature measurements are received before the course of treatment.
11. The method of claim 1, wherein the first set of one or more biological temperature measurements are received after the course of treatment, and the second set of one or more biological temperature measurements are received during the course of treatment.
12. The method of claim 1, wherein one or more of the first set of one more biological temperature measurements or the second set of one or more biological temperature measurements are received after cessation of the course of treatment13. The method of claim 1, further comprising implanting the first oncology monitoring device at the target location within the subject.
14. The method of claim 13, further comprising implanting a second oncology monitoring device having a second temperature sensor at the control location within the subject.
15. The method of claim 1, wherein: the first oncology monitoring device includes one or more of a pH sensor, an oxygen sensor, or a glucose sensor; the method includes receiving one or more of a first pH value, a first oxygen value, or a first glucose value, obtained from one or more of the pH sensor, the oxygen sensor, or the glucose level sensor; and the method includes receiving one or more of a second pH value, a second oxygen value, or a second glucose value, obtained from one or more of the pH sensor, the oxygen sensor, or the glucose level sensor.
16. The method of claim 15, further comprising: comparing the first pH value with the second pH value to generate a first pH differential measurement; and generating the health status metric of the subject includes using the first pH differential measurement and the first temperature differential measurement.
17. The method of claim 15, further comprising:comparing the first oxygen value with the second oxygen value to generate a first oxygen differential measurement; and generating the health status metric of the subject includes using the first oxygen differential measurement and the first temperature differential measurement.
18. The method of claim 15, further comprising: comparing the first glucose value with the second glucose value to generate a first glucose differential measurement; and generating the health status metric of the subject includes using the first glucose differential measurement.
19. The method of claim 1, wherein a health status metric generator includes a machine learning algorithm trained with one or more measured physiological characteristics from a plurality of training subjects where the course of treatment was effective in treating the plurality of treated subjects.
20. The method of claim 19, wherein the health status metric generator uses the machine learning algorithm to generate the health status metric.
21. The method of claim 19, wherein the machine learning algorithm is trained with a combination of measured physiological characteristics, from the plurality of training subjects where the course of treatment was effective in treating the plurality of training subjects, including two or more of temperature, pH, oxygen, or glucose.
22. The method of claim 19, wherein the health status metric includes an indication of whether the course of treatment is effective in treating the cancerous tissue of the subject.
23. The method of claim 1, wherein the health status metric includes an indication of whether the course of treatment is effective in treating the cancerous tissue of the subject.
24. The method of claims 22 or 23, further comprising continuing the course of treatment based on the indication of whether the course of treatment is effective in treating the cancerous tissue of the subject.
25. The method of claims 22 or 23, further comprising discontinuing the course of treatment based on the indication of whether the course of treatment is effective in treating the cancerous tissue of the subject.
26. The method of claims 22 or 23, further comprising changing the course of treatment based on the indication of whether the course of treatment is effective in treating the cancerous tissue of the subject.
27. A computer-implemented method for monitoring a subject of an oncology medical treatment, the method comprising: storing an identifier for the subject in a database in memory circuitry of a computing device; and storing an identifier for a temperature sensor enabled implantable oncology monitoring device implanted within the subject in the database in memory circuitry of the computing device, in association with the stored identifier for the subject.
28. The method of claim 27, further comprising storing, in the database, a first set of temperature measurements obtained from the implantable oncology monitoring device.
29. The method of claim 27, further comprising storing, in the database, treatment information related to the subject.30 The method of claim 27, further comprising storing, in the database, information related to implantation of the oncology monitoring device within the subject including one or more of location or orientation of the device implanted within the subject.
31. The method of claim 27, further comprising storing, in the database, information related to the subject, including one or more of abnormal body tissue or pathologies present with the subject.
32. The method of claim 27, wherein at least the identifier for the subject and the identifier for the temperature sensor are stored in a manner to comply with at least HIPAA.
33. A system for monitoring one or more physiological characteristics of a human or animal subject, the system comprising: a first oncology monitoring device configured to measure at least a first set of one or more physiological parameters at a first time and a second set of one or more physiological parameters at a second time, wherein: the first time is prior to, or concurrent with, treatment provided to the subject; the second time is after treatment provided to the subject; and the first oncology monitoring device is configured for implantation in the subject; and a database and information processing system, including: a device interface configured for communication with the first oncology monitoring device, wherein the device interface is configured to receive measured first and second sets of one or more physiological parameters; memory circuitry configured to store at least the first and second sets of one or more physiological parameters; an information comparator configured to compare the first set of physiological characteristics with the second set of physiological characteristics; and a health status metric generator configured to generate a health status metric based on the comparison of the first set of physiological characteristics with the second set of physiological characteristics, wherein the health status metric corresponds with efficacy of treatment provided to the subject.
34. The system of claim 33, further comprising a second oncology monitoring device configured to measure at least a third set of one or more physiological parameters at one or more of the first time or the second time, wherein the second device is configured for implantation in the subject.
Citation Information
Patent Citations
Methods and systems for monitoring patients undergoing treatment for cancer
US20100268078A1
Computer-aided simulation tool for providing assistance in the planning of thermotherapy
US20140149092A1
Method and apparatus for biological evaluation
US20150094914A1
Aggregating and analyzing drug administration data
US20210350897A1
Apparatus and methods for administration of medicine including monitoring and user feedback
US20230226272A1
